暂无分享,去创建一个
Viktor H. Koelzer | Tjalling Bosse | Remi A. Nout | Jiqing Wu | Nanda Horeweg | Marco de Bruyn | Ina M. Jürgenliemk-Schulz | Ludy C. H. W. Lutgens | Jan J. Jobsen | Elzbieta M. van der Steen-Banasik | Hans W. Nijman | Vincent T. H. B. M. Smit | Carien L. Creutzberg | T. Bosse | E. M. van der Steen-Banasik | V. Smit | N. Horeweg | I. Jürgenliemk-Schulz | R. Nout | V. Koelzer | H. Nijman | C. Creutzberg | J. Jobsen | M. de Bruyn | L. Lutgens | Ji Q. Wu
[1] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[2] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[3] Jian Peng,et al. When causal inference meets deep learning , 2020, Nature Machine Intelligence.
[4] F. Wilcoxon. Individual Comparisons by Ranking Methods , 1945 .
[5] Hector Zenil,et al. Causal deconvolution by algorithmic generative models , 2019, Nature Machine Intelligence.
[6] Rémi,et al. Endometrium FIFTEEN-YEAR RADIOTHERAPY OUTCOMES OF THE RANDOMIZED PORTEC-1 TRIAL FOR ENDOMETRIAL CARCINOMA , 2011 .
[7] T. Bosse,et al. Incorporation of molecular characteristics into endometrial cancer management , 2019, Histopathology.
[8] P. Koper,et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. , 2005, International journal of radiation oncology, biology, physics.
[9] P. Koper,et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.
[10] P. Pollock,et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative , 2015, Modern Pathology.
[11] T. Bosse,et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy , 2020, International Journal of Gynecological Cancer.
[12] Swarat Chaudhuri,et al. HOUDINI: Lifelong Learning as Program Synthesis , 2018, NeurIPS.
[13] Mario Lucic,et al. Are GANs Created Equal? A Large-Scale Study , 2017, NeurIPS.
[14] Samuel Leung,et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification , 2017, The journal of pathology. Clinical research.
[15] Chris Hawblitzel,et al. Safe to the last instruction: automated verification of a type-safe operating system , 2010, PLDI '10.
[16] H. Putter,et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy , 2018, British Journal of Cancer.
[17] Bibb Allen. The Role of the FDA in Ensuring the Safety and Efficacy of Artificial Intelligence Software and Devices. , 2019, Journal of the American College of Radiology : JACR.
[18] Jonas Peters,et al. Causal inference by using invariant prediction: identification and confidence intervals , 2015, 1501.01332.
[19] Robert Platt,et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. , 2016, Journal of clinical epidemiology.
[20] D. Lambrechts,et al. Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.
[21] Chuang Gan,et al. The Neuro-Symbolic Concept Learner: Interpreting Scenes Words and Sentences from Natural Supervision , 2019, ICLR.
[22] Marcus Rohrbach,et al. Probabilistic Neural-symbolic Models for Interpretable Visual Question Answering , 2019, ICML.
[23] Heather Dawson,et al. Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types , 2013, Journal of Translational Medicine.
[24] Jimmy Ba,et al. Adam: A Method for Stochastic Optimization , 2014, ICLR.
[25] T. Bosse,et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. , 2014, European journal of cancer.
[26] M. Kloor,et al. The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.
[27] H. Putter,et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.
[28] Issa J Dahabreh,et al. Extending inferences from a randomized trial to a new target population , 2018, Statistics in Medicine.
[29] M. Rugge,et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial , 2017, JAMA oncology.
[30] T. Bosse,et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.
[31] Christina Heinze-Deml,et al. Invariant Causal Prediction for Nonlinear Models , 2017, Journal of Causal Inference.
[32] Zhitang Chen,et al. Causal Discovery with Reinforcement Learning , 2019, ICLR.
[33] P. Lambin,et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. , 2015, International journal of radiation oncology, biology, physics.
[34] J. Pearl. Causal inference in statistics: An overview , 2009 .
[35] C. Villani. Optimal Transport: Old and New , 2008 .
[36] H. Putter,et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Locascio,et al. Randomised controlled trials – the gold standard for effectiveness research , 2018, BJOG : an international journal of obstetrics and gynaecology.
[38] M. Hernán,et al. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes , 2018, AIDS.
[39] A. Talhouk,et al. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma , 2018, Clinical Cancer Research.
[40] H. Putter,et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.
[41] Spiros C. Denaxas,et al. Avoidable flaws in observational analyses: an application to statins and cancer , 2019, Nature Medicine.
[42] M. Lipsitch,et al. Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.
[43] Armando Solar-Lezama,et al. DreamCoder: growing generalizable, interpretable knowledge with wake–sleep Bayesian program learning , 2020, Philosophical Transactions of the Royal Society A.
[44] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[45] Marc Brockschmidt,et al. Differentiable Programs with Neural Libraries , 2016, ICML.
[46] K. Mertz,et al. Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer , 2020, Cancer Immunology Research.
[47] Judea Pearl,et al. Causal Inference in the Health Sciences: A Conceptual Introduction , 2001, Health Services and Outcomes Research Methodology.
[48] Jens Rittscher,et al. Precision immunoprofiling by image analysis and artificial intelligence , 2018, Virchows Archiv.
[49] Jiang Bian,et al. Causal inference and counterfactual prediction in machine learning for actionable healthcare , 2020, Nature Machine Intelligence.
[50] J. Pfanzagl,et al. Studies in the history of probability and statistics XLIV A forerunner of the t-distribution , 1996 .
[51] Juan L Gamella,et al. Active Invariant Causal Prediction: Experiment Selection through Stability , 2020, NeurIPS.
[52] Chandler Squires,et al. ABCD-Strategy: Budgeted Experimental Design for Targeted Causal Structure Discovery , 2019, AISTATS.
[53] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[54] H. Mackay,et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer , 2016, Modern Pathology.
[55] Sepp Hochreiter,et al. GANs Trained by a Two Time-Scale Update Rule Converge to a Local Nash Equilibrium , 2017, NIPS.
[56] H. Levene. Robust tests for equality of variances , 1961 .
[57] Ida Scheel,et al. Time-to-Event Prediction with Neural Networks and Cox Regression , 2019, J. Mach. Learn. Res..